동물 위식도 역류질환(GERD) 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Animal Gastroesophageal Reflux Disease Market was valued at USD 3.1 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 6.3 billion by 2034, driven by the increasing prevalence of GERD among both companion and livestock animals, as well as advancements in veterinary diagnostics and treatments. Factors such as aging populations, obesity, and gastrointestinal infections contribute to the development of GERD in animals, leading to a higher demand for effective treatment options. The market is characterized by the availability of various diagnostic tools and therapeutic interventions, including antacids, H2 antagonists, and proton pump inhibitors, which are widely used in veterinary medicine to manage GERD symptoms. These medications help reduce stomach acid and are commonly prescribed due to their proven safety and efficacy profiles in animals.

In addition, advancements in veterinary diagnostics, such as endoscopic imaging, advanced blood panels, and ultrasound technologies, are making it easier for veterinarians to detect GERD earlier and with greater precision. This has led to an uptick in early intervention strategies, which can significantly improve outcomes and reduce long-term complications. The increasing awareness among pet owners about the impact of digestive disorders on overall pet health is also accelerating demand for both over-the-counter and prescription solutions.

The treatment segment in the animal gastroesophageal reflux disease market generated USD 1.7 billion in 2024. Medications such as antacids, H2 antagonists, and proton pump inhibitors have shown consistent effectiveness in reducing stomach acid in animals, which is crucial for controlling GERD symptoms. These medications are widely available in both human and veterinary formulations and have been used in veterinary medicine for years due to their safety and minimal side effects.

The companion animals segment held the largest share of 71.7% in 2024. Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. Dietary issues often lead to the development of acid reflux, increasing the need for GERD treatment options. Certain dog breeds, such as pugs, bulldogs, and boxers, are particularly susceptible to GERD due to their unique anatomical features.

United States Animal Gastroesophageal Reflux Disease Market was valued at USD 1.2 billion in 2024, owing to the increasing number of pet ownership and the growing demand for veterinary services. There is a rising awareness among pet owners and livestock breeders regarding the importance of gastrointestinal health and its impact on overall animal well-being. Government initiatives focusing on disease prevention and animal welfare further support market growth.

Key players in the Global Animal Gastroesophageal Reflux Disease Market include Boehringer Ingelheim, Zoetis, Merck, Elanco, Hill's Pet Nutrition, IDEXX Laboratories, Kerry Group, Vetcare, Vetoquinol, and Virbac. These companies are actively involved in developing and offering a range of diagnostic and therapeutic solutions to address GERD in animals. Their efforts aim to improve the quality of life for affected animals and meet the growing demand for effective treatments in the veterinary sector. To strengthen their market position, companies in the animal GERD market are adopting various strategies. They are focusing on research and development to introduce innovative diagnostic tools and treatment options. Collaborations with veterinary clinics and research institutions are being pursued to enhance product offerings and expand market reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal diseases in animals
    • 3.2.1.2 Rising awareness of animal health
    • 3.2.1.3 Technological advancements in diagnostic tools
    • 3.2.1.4 Increased pet ownership and pet humanization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory challenges and reliability concerns
    • 3.2.2.2 High cost of endoscopic and pH monitoring procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostics
  • 5.2.1 Test type
    • 5.2.1.1 Laboratory tests
    • 5.2.1.2 Veterinary imaging
    • 5.2.1.3 Other diagnostic tests
  • 5.2.2 End use
    • 5.2.2.1 Veterinary hospital and clinics
    • 5.2.2.2 Veterinary diagnostic centers
    • 5.2.2.3 Other end use
• 5.3 Treatment
  • 5.3.1 Drug class
    • 5.3.1.1 Antacids
    • 5.3.1.2 H2 receptor blockers
    • 5.3.1.3 Proton pump inhibitors (PPIs)
    • 5.3.1.4 Pro-kinetic agents
    • 5.3.1.5 Other drug classes
  • 5.3.2 Route of administration
    • 5.3.2.1 Oral
    • 5.3.2.2 Injectables

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
• 6.3 Livestock animals

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Boehringer Ingelheim
• 8.2 Daiichi Sankyo
• 8.3 Elanco Animal Health
• 8.4 Hill's Pet Nutrition
• 8.5 IDEXX Laboratories
• 8.6 Kerry Group
• 8.7 Merck
• 8.8 Vetcare
• 8.9 Vetoquinol
• 8.10 Vibrac
• 8.11 Zoetis